Immuno-Oncology Drug Development: Current Pipeline and Trends
Immuno-Oncology Drug Development: Current Pipeline and Trends
1. Global Pipeline Scale & Modality Distribution
The immuno-oncology drug development pipeline now encompasses more than 4,800 molecules in preclinical through registration stages. While checkpoint inhibitors remain a backbone, the modality mix is diversifying rapidly. Cell therapies (CAR-T, NK, gamma-delta T) and bispecific antibodies represent the fastest-growing segments.
● 4,830+ active IO assets worldwide (2025), up from ~1,100 in 2015 — a 340% increase.
● 38% of pipeline assets are cell or gene therapies, compared to 22% in 2020 (+16 pp shift).
● Bispecific antibodies now constitute 12.4% of all IO clinical-stage assets, with over 180 molecules in Phase I/II.
● Checkpoint inhibitors (anti-PD-1/PD-L1, CTLA-4) still dominate late-stage trials but represent only 27% of early-stage pipeline (down from 41% in 2021).
This shift reflects a strategic move beyond PD-1/PD-L1 axis toward novel immune checkpoints (LAG-3, TIGIT, VISTA), innate immune agonists (STING, TLR), and tumor microenvironment modulators. The percentage of “first-in-class” mechanisms in early clinical phases has climbed to 44% (2025), indicating growing appetite for non-traditional targets.
2. Therapeutic Area Focus & Biomarker Integration
Solid tumors account for ~73% of the IO pipeline, but hematologic malignancies maintain a disproportionately high share of late-stage cell therapies. Biomarker stratification is now embedded in over 60% of Phase II/III trials, with tumor mutational burden (TMB), microsatellite instability (MSI), and PD-L1 expression remaining the most common classifiers.
● 73% of pipeline programs target solid tumors; 27% target hematologic cancers (2025).
● 62% of Phase II/III IO trials include a biomarker-driven enrollment strategy (up from 41% in 2020).
● Liquid biopsy integration (ctDNA, exosomes) increased by 28% year-over-year, now used in 1 in 3 IO trials.
● Multi-omics signatures (RNA-seq, proteomics) are used in 19% of early-stage IO discovery programs.
Notably, the use of “agnostic” biomarkers (e.g., TMB-H, MSI-H) has expanded beyond checkpoint inhibitors into novel IO combinations. Approximately 1 in 5 pipeline assets now carry a biomarker label or co-development plan, reflecting regulatory preference for enriched patient populations.
3. Combination Strategies & Resistance Breaking
Monotherapy development is declining sharply. Over 70% of IO assets in Phase II or later are being developed as part of a combination regimen. The most common backbones remain anti-PD-1/PD-L1 agents, but combinations with targeted therapies (KRAS G12C, EGFR, PARP) and novel IO-IO pairs (e.g., PD-1 + TIGIT, PD-1 + LAG-3) have surged.
● 72% of late-stage IO trials involve combination therapy (2025), up from 54% in 2019.
● IO + IO combinations grew 2.3x since 2022, now representing 31% of all combination trials.
● IO + targeted therapy (including antibody-drug conjugates) accounts for 28% of combination pipeline.
● Resistance-overcoming strategies (bispecifics targeting dual checkpoints, armored CARs) increased by 41% in preclinical/Phase I since 2023.
Resistance mechanisms (adaptive immune evasion, antigen escape, T-cell exhaustion) are being addressed through next-generation IO constructs. For example, “armored” CAR-T cells expressing IL-15 or dominant-negative TGF-beta receptors now represent 14% of CAR-T pipeline assets. Similarly, conditionally activated bispecifics (Probody®-like) aim to reduce on-target off-tumor toxicity.
4. Regional Dynamics & Early-Stage Innovation
North America and China together host ~68% of IO pipeline assets, but the share of Asian-origin (ex-China) programs has grown to 11%. Early-stage (preclinical/Phase I) assets account for 58% of the total IO pipeline, signaling a strong innovation influx. However, the attrition rate remains high: only ~12% of Phase I IO assets eventually reach registration.
● US-based sponsors lead with 42% of global IO pipeline assets; China accounts for 26% (up from 15% in 2020).
● European IO pipeline share declined to 18% (from 24% in 2019), though still significant in bispecifics.
● Preclinical-stage IO assets grew 33% in the last 2 years, now representing 58% of total pipeline.
● Phase I-to-registration success rate for IO assets is 11.8% (vs. ~7% for all oncology drugs).
China’s rapid expansion is driven by a wave of PD-1/PD-L1 biosimilars and novel IO combinations, but also by first-in-class molecules targeting CD47, CLDN18.2, and NKG2A. Meanwhile, the US maintains leadership in cell therapy and bispecific innovation. The number of IO assets with orphan drug designation has risen to 34% of the pipeline, reflecting a focus on niche, biomarker-defined populations.
5. Emerging Modalities & Technology Convergence
Beyond classical antibodies and cell therapies, the IO pipeline is absorbing novel modalities: mRNA-based immunotherapies (cancer vaccines, encoded cytokines), oncolytic viruses, and targeted radionuclide-immune conjugates. Nearly 1 in 5 preclinical IO assets now uses a non-protein modality, a trend that is reshaping manufacturing and regulatory frameworks.
● mRNA-based IO assets (vaccines + encoded biologics) grew 2.7x since 2022, now >110 candidates.
● Oncolytic virus pipeline: 64 assets (2025), with 22 in Phase II/III; combination with checkpoint inhibitors is standard.
● Radioligand-immune conjugates (e.g., 225Ac-labeled PD-L1) represent a new class with 18 disclosed assets.
● AI/ML-designed IO biologics (de novo protein design) appear in 7% of early discovery pipelines (up from <1% in 2021).
Convergence of IO with precision radiotherapy, bispecific T-cell engagers, and synthetic biology (logic-gated CARs) is accelerating. The first “digital” biomarkers (AI-derived from H&E slides) are being integrated into IO trial design, with at least 15 Phase II/III trials using computational pathology for patient selection.
Frequently Asked Questions
❓ What is the current size of the immuno-oncology drug development pipeline?
As of mid-2025, the global IO pipeline includes more than 4,830 active assets spanning preclinical through registration. This represents a 340% increase over the past decade, with cell therapies and bispecifics being the fastest-growing categories.
❓ Which modalities dominate the IO pipeline in 2025?
Checkpoint inhibitors remain important (27% of early-stage), but cell and gene therapies now represent 38% of all assets. Bispecific antibodies account for 12.4% of clinical-stage molecules, while mRNA-based immunotherapies and oncolytic viruses are emerging rapidly.
❓ How important are biomarkers in IO drug development today?
Biomarker-driven enrollment is used in 62% of Phase II/III IO trials, up from 41% in 2020. Liquid biopsy integration (ctDNA) increased 28% year-over-year, and multi-omics signatures are now part of 19% of early discovery programs.
❓ What are the key trends in IO combination strategies?
Over 72% of late-stage IO trials involve combinations. The most dynamic area is IO + IO (e.g., PD-1 + TIGIT, PD-1 + LAG-3), which grew 2.3x since 2022. IO + targeted therapy (including ADCs) accounts for 28% of combination pipeline.
❓ Which regions lead IO pipeline innovation?
North America (42%) and China (26%) together hold the majority of IO assets. China’s share has grown from 15% in 2020, driven by PD-1 biosimilars and novel targets like CD47. Europe’s share declined to 18%, though it remains strong in bispecific development.